LAG3 and melanoma: According to the latest progress, a phase II-III study, RELATIVITY-047, demonstrated that the combination of nivolumab and relatlimab (a LAG-3 inhibitor) improved progression-free survival (PFS) in advanced melanoma patients with comparable adverse events, which promoted the approval of the combination of nivolumab and relatlimab for the first-line treatment of advanced melanoma by FDA [41].